Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Short Interest Up 32.9% in March

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) was the target of a significant increase in short interest in March. As of March 13th, there was short interest totaling 715,845 shares, an increase of 32.9% from the February 26th total of 538,588 shares. Currently, 74.0% of the shares of the stock are sold short. Based on an average daily volume of 127,665 shares, the short-interest ratio is presently 5.6 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Sensei Biotherapeutics stock. Renaissance Technologies LLC increased its stake in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 10.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 11,516 shares of the company’s stock after acquiring an additional 1,100 shares during the period. Renaissance Technologies LLC owned about 0.91% of Sensei Biotherapeutics worth $123,000 as of its most recent SEC filing. Institutional investors and hedge funds own 10.50% of the company’s stock.

Analyst Ratings Changes

SNSE has been the topic of several research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sensei Biotherapeutics in a report on Monday, December 29th. Wall Street Zen upgraded shares of Sensei Biotherapeutics to a “hold” rating in a research report on Saturday, December 27th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Sensei Biotherapeutics presently has an average rating of “Hold” and a consensus target price of $30.00.

Sensei Biotherapeutics Trading Up 6.2%

Shares of SNSE stock traded up $1.55 on Tuesday, hitting $26.68. The stock had a trading volume of 77,500 shares, compared to its average volume of 321,238. Sensei Biotherapeutics has a twelve month low of $5.00 and a twelve month high of $36.76. The company has a fifty day moving average price of $21.50 and a two-hundred day moving average price of $13.88. The firm has a market cap of $33.62 million, a P/E ratio of -1.39 and a beta of -0.14.

Sensei Biotherapeutics (NASDAQ:SNSE) last released its quarterly earnings data on Monday, March 30th. The company reported ($3.74) earnings per share for the quarter, beating the consensus estimate of ($4.81) by $1.07. On average, analysts expect that Sensei Biotherapeutics will post -1.17 earnings per share for the current year.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.